Dupilumab efficacy in adolescents with uncontrolled, moderate-to-severe asthma: LIBERTY ASTHMA QUEST
Jorge F Maspero, John Mark FitzGerald, Ian D Pavord, Megan S Rice, Jaman Maroni, Paul J Rowe, Gianluca Pirozzi, Nikhil Amin, Marcella Ruddy, Neil M H Graham, Ariel Teper, Megan Hardin, Jorge F Maspero, John Mark FitzGerald, Ian D Pavord, Megan S Rice, Jaman Maroni, Paul J Rowe, Gianluca Pirozzi, Nikhil Amin, Marcella Ruddy, Neil M H Graham, Ariel Teper, Megan Hardin
No abstract availableKeywords: asthma; asthma treatment; biologics; biomarkers; interleukins.
Conflict of interest statement
Maspero JF: AstraZeneca, Sanofi—consultant; GlaxoSmithKline, Menarini, Novartis, Uriach—speaker fees; Novartis—research grants. FitzGerald JM: AstraZeneca, GlaxoSmithKline, Novartis, Teva—advisory board; AstraZeneca, GlaxoSmithKline, Regeneron Pharmaceuticals, Inc., Sanofi—research funding paid directly to UBC; GlaxoSmithKline—unrestricted grants; AstraZeneca, GlaxoSmithKline, Novartis—speaker honoraria; Vancouver Coastal Health—educational material. Pavord ID: Aerocrine, Almirall, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Teva—speakers’ honoraria; AstraZeneca, Teva—organization of educational events; Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Dey Pharma, Genentech, GlaxoSmithKline, Knopp Biosciences, Merck, Merck Sharp & Dohme, Napp Pharmaceuticals, Novartis, Regeneron Pharmaceuticals, Inc., RespiVert, Sanofi, Schering‐Plough, Teva—advisory boards; AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Napp Pharmaceuticals, Teva—traveling grants; Chiesi—clinical trial support. Rice MS, Rowe P, Hardin M: Sanofi—employees, may hold stock and/or stock options in the company. Maroni J, Amin N, Ruddy M: Regeneron Pharmaceuticals, Inc.—employees and shareholders. Pirozzi G, Teper A: Sanofi—former employees, may hold stock and/or stock options in the company. Graham NMH: Regeneron Pharmaceuticals, Inc.—former employee and shareholder.
Figures
References
- Ferrante G, La Grutta S. The burden of pediatric asthma. Front Pediatr. 2018;6:186.
- MacDonald LE, Karow M, Stevens S, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci. 2014;111(14):5147‐5152.
- Murphy AJ, Macdonald LE, Stevens S, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci USA 2014;111:5153‐5158.
- Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL‐4/IL‐13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425‐437.
- Le Floc’h A, Allinne J, Nagashima K, et al. Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy 2020;75(5):1188‐1204.
- Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate‐to‐severe uncontrolled asthma. N Engl JMed. 2018;378(26):2486‐2496.
Source: PubMed